Investigating the effect of Metformin and Aspirin on the prevention of Preeclampsia

Investigating the effect of Metformin and Aspirin compared to Aspirin on the prevention of Preeclampsia and the duration of pregnancy and some maternal and neonatal outcomes

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20251031067831N1

Enrollment

146

Registered

2026-02-16

Start date

2025-12-15

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preeclampsia.

Interventions

Intervention group: Metformin receiving group.

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Pregnant mothers aged 18 to 45 years - gestational age 12 to 20 weeks Mothers who are at moderate or high risk for preeclampsia according to the ACOG risk assessment table Serum PAPP-A marker level at 12 weeks screening is less than 0.5 MOM Mean bilateral uterine artery resistance index (PI) is greater than the 95th percentile for gestational age, on NT sonography (12 minutes) or anomalous ultrasound scan at 18 to 19 weeks.

Exclusion criteria

Exclusion criteria: Sensitivity to metformin - maternal lack of consent to taking the medication Major abnormality in anomalous scan Abnormal karyotype on CVS (chorionic villus sampling) or amniocentesis

Design outcomes

Primary

Measure	Time frame
Preventing preeclampsia in high-risk mothers. Timepoint: Once every two weeks. Method of measurement: Questionnaire and data collection form.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSima Ghobadi

Yasouj University of Medical Sciences

ahmadimche@gmail.com+98 74 3222 0163

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026